The first person to live to 150 has already been born
Our biological destiny is transforming like never before. In 1900, you would be lucky to live for 50 years; today, 50 is arguably the new 30. Advances in science, medicine, and technology have not only prolonged our lives but they’ve allowed us to stay healthy into our 70s and beyond. Our track record in beating once fatal diseases is also improving dramatically: The five-year survival rate for men with prostate cancer has risen from 69 percent in the 1970s to 100 percent in 2007.
A brave new world of medicine
Many of today’s most promising diagnostics and treatments are occurring at the intersection of biology, physics and digital technology.
We have started to understand how to edit human genes and to make replacement organs using 3D printing technology. Surgeons rely on robotic systems to perform complex operations, while researchers mine big data to drive drug discovery. Advances in genomics are swinging the doors wide open to precision medicine, allowing us to apply therapies targeting diseases at the molecular level rather than one-size-fits-all treatments that only alleviate symptoms.
Human Evolution Innovation Exposure
As we reshape our biological evolution through the convergence of multiple domains, it’s an opportune moment to invest in innovations that reimagine medicine and healthcare. The Goldman Sachs GDNA ETF, a component of our Next Wave of Innovation portfolio, allows you to gain exposure to businesses that are ushering in medicine and healthcare’s next frontiers.
The content contained herein is for informational purposes only and is not a solicitation or a recommendation that any particular investor should purchase or sell any particular security. Motif does not assess the suitability or the potential value of any particular investment. You are responsible for understanding the risks involved with investing in securities and for all investment decisions you make. Investments in small cap companies and companies within a particular sector involve additional risks unique to those companies which you should be aware of before making any investment decision. The information contained herein is obtained from sources believed to be reliable, but its accuracy or completeness is not guaranteed.
Investing in securities involves risk, including the possible loss of principal; individual investments or a collection of individual stocks such as Motifs which are concentrated in an idea or theme may face increased risk of price fluctuation over more diversified holdings due to adverse developments within a particular industry or sector; diversification does not assure or guarantee better performance and cannot eliminate the risk of investment loss; past performance does not guarantee future results; please consult the investment prospectus for additional information on risk.
Motif Capital Management, Inc., is an SEC-registered investment adviser and a separate, wholly-owned subsidiary of Motif Investing, Inc., a registered broker-dealer and member SIPC.